1 / 28

Rice paper cont.

Rice paper cont. TPA = Tissue plasminogen activator, dissolves clots Problem: Cleared quickly from bloodstream by liver Bind to hepatocytes in liver via TPA’s kringle domain Want to isolate a TPA mutant protein with less affinity for hepatocytes Must be still enzymatically active of course.

inga
Download Presentation

Rice paper cont.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rice paper cont. TPA = Tissue plasminogen activator, dissolves clots Problem: Cleared quickly from bloodstream by liver Bind to hepatocytes in liver via TPA’s kringle domain Want to isolate a TPA mutant protein with less affinity for hepatocytes Must be still enzymatically active of course.

  2. Goal: to improve tissue plasminogen activator as a therapeutic “clot-busting” treatment Means: Reduce or eiminate the binding of tPA to liver cells, as this clears it from the blood Authors here use a mammalian cells as the carrier of the DNA and the cell surface as a display site. Display was via a fusion protein to a membrane anchor protein, DAF (peptide, really). DAF = “decay accelerating factor” What did they do? Cassette mutagenesis. What region? 333 bp K1 (kringle-1), known to bind the MAb387, which competes for hepatocyte binding (so assuming it is the same target epitope). How did they get kringle mutated? Error-prone PCR How did they isolate just the kringle 1 region? PCR fragment. How did they get the mutagenized fragment back in? Introduced restriction sites at the ends, w/o affecting the coding.

  3. What did they put the mutagenized fragment into? DAF – TPA fusion protein geneHow did they get it into into cells? Electroporation What cells did they use as hosts? 293 carrying SV40 large T antigen How many copies per cell. And why is that important? One, by electroporation at low DNA concentration. [In a transient transfection!] Binding is dominant. Lack of binding (what they are after) is recessive. How did they select cells making MAb387-non-binding TPA? FACS: Recover cells that bind fluorescent mAb vs. protease domainbut low binding to fluorescent mAb vs. kringle domain

  4. Tracked down vector: contains SV40 ori and is transfected into 293 cells making SV40 T-antigen. So plasmid replicates during the transient transfection  higher signal.

  5. , Sort the cells with low fluorescence For reiteration of the process

  6. How did they recover the plasmid carrying the mutant TPA gene from the selected cells? Hirt extraction: Like a plasmid prep, lyse cells gently, high MW DNA entangles and forms a “clot”. Centrifuge. Chromosomal DNA  soft pellet; plasmid DNA circles stay in supernatant. Then re-transfect, re-sort in FACS. After 2 sorting rounds, test individual E. coli clones: 60% are binding-negative.

  7. MAb to protease domain enriched Collect these No good good good good good Low kringle-1 reactivity MAb to kringle-1 domain FITC = fluorescein reagent. PE = phycoerythrin (fluorescent protein)

  8. Hepatoma cell binding. How? Clone mutated regions into regular TPA gene for testing (no DAF, protein now secreted) Label WT TPA with fluorescein (FITC, conjugated chemically) Mix with hepatoma cells and analyze on a flow cytometer (FACS w/o the sorter part). See specific and non-specific binding. Subtract non-specific binding: the amount not competed by excess un-labeled wt TPA. FITC = fluorescein isothiocyanate

  9. Can’t compete (good) But still haveprotease activity Hepatoma cell binding assay: measure competition for binding of fluorescently labeled WT TPA Binding assay, initial condition No competitor WT Compete. So still bind.

  10. Mammalian cell genetics Introduction: Genetics as a subject (genetic processes that go on in somatic cells: that replicate, transmit, recombine, and express genes) Genetics as a tool. Most useful the less you know about a process. 4 manipulations of genetics: 1- Mutation: in vivo (chance + selection, usually); targeted gene knock-out or alteration in vitro: site directed or random cassette 2- Mapping: Organismic mating segregation, recombination (e.g., transgenic mice); Cell culture: cell fusion + segregation; radiation hybrids; FISH 3- Gene juxtaposition (complementation): Organisms: matings  phenotypes of heterozygotes; Cell culture: cell fusion  heterokaryons or hybrid cells 4- Gene transfer: transfection

  11. Mammalian cell genetics Advantages of cultured cells (vs. whole organism): numbers, homogeneity Disadvantages of cultured mammalian cells: limited phenotypes limited differentiation in culture (but some phenotypes available) no sex (cf. yeast) Mammalian cell lines Most genetic manipulations use permanent lines, for the ability to do multiple clonings Primary, secondary cultures, passages, senescence. Crisis, established cell lines, immortality vs. unregulated growth. Most permanent lines = immortalized, plus "transformed“, (plus have abnormal karyotypes)

  12. Mutation in cultured mammalian cells: Problem of epigenetic change: Variants vs. mutants Variants could be due to: Stable heritable alterations in phenotype that are not due to mutations: heritable switches in gene regulation (we don’t yet understand this). DNA CpG methylation, histone acetylation / de-acetylation Diploidy. Heteroploidy. Haploidy. The problem of diploidy and heteroploidy: Recessive mutations (most knock outs) are masked. (cf. e.g., yeast, or C. elegans, Dros., mice): F2  homozygotes)

  13. Solutions to diploidy problem: Double mutants (incl. also mutation + segregation, or mutation + homozygosis:(rare but does occur) Heavy mutagenesis, mutants/survivor increases but mutants/ml decreases. How hard is it to get mutants? What are the spontaneous and induced mutation rates? (loss of function mutants) Spont: ~ 10-7/cell-generation Induced: ~ 2 x 10-4 to 10-3/cell(EMS, UV) So double knockout could be 0.00072~ 5X10-7.One 10cm tissue culture dish holds ~ 5x106 cells. Note: Same considerations for creation of recessive tumor suppressor genes in cancer: requires a double knockout. But there are lots of cells in a human tissue or in a mouse. RNAi screen, should knock down both alleles: Transfect with a library of cDNA fragments designed to cover all mRNAs. Select for knockout phenotype (may require cleverness). Clone cells and recover RNAi to identify target gene. A human near haploid cell strain. Use of it: Science, 326: 1231-1235 (2009) EMS = ethyl methanesulfonate: ethylates guanine UV (260nm): induces dimers between two adjacent pyrimidines on the same DNA strand

  14. L R R L Homozygosis: Loss of heterozygosity (LOH)by mitotic recombination between homologous chromosomes (rare) M i t o s i s - - - + + 2 heterozygotes again L R L R L R R L or - - + + - - + + Paternal Chr. 4, say Maternal Chr. 4 - - Recombinant chromatids + + After homologous recombination (not sister chromatid exchange) Heterozygote 1 homozygote +/+1 homozygote -/- Recessive phenotype is unmasked = a mechanism of homozygosis of recessive tumor suppressor mutations in cancer

  15. Mutagenesis (induced general mutations, not site directed) Chemical and physical agents: MNNG point mutations (single base substitutions) EMS “ “ Bleomycin small deletions UV mostly point mutations but also large deletions Ionizing radiation (X-, gamma-rays) large deletions, rearrangements Dominant vs. recessive mutations; Dom. are rare (subtle change in protein), but expression easily observed, Recessives are easier to get (whatever KO’s the protein function), but their expression is masked by the WT allele.

  16. Categories of cell mutant selections Example • Auxotrophs purine- • Drug resistance Dominant ouabainR, alpha-amanitinR Recessive 6TGr, BrdUr • Antibodies vs. surface components MHC- • Visual inspection G6PD-, Ig IP- • FACS = fluorescence‑activated cell sorter DHFR- • Brute force IgG-, electrophoretic shifts • Temperature‑sensitive mutants 3H-leu resistant

  17. Purine biosynthesis, salvage pathways, and inhibitors Adenine(A) (diaminopurine) (8-azaadenine) Methotrexate Folate (=amethopterin) (~aminopterin) Adenosine APRT Adenosine FH4 kinase Nuc. Acid AMP Glycine Thymidine (T) Adenylosucc. Alanosine PRPP + IMP glutamine HGPRT Azaserine XMP GMP Nuc. Acid Hypoxanthine Glutamine XGPRT HGPRT (H) (Eco gpt) Guanine Xanthine Mycophenolic (6-thioguanine) (X) acid (8-azaguanine) Salvage enzymes Biosynthesis; Analogs (iytal.) Code: Inhibitors (drugs, in italics) PRPP = phosphoribosyl pyrophosphate; FH4=tetrahydrofolate

  18. Purine biosynthesis, salvage pathways, and inhibitors Adenine(A) (diaminopurine, DAP) (8-azaadenine, 8AA) Methotrexate Folate (=amethopterin) (~aminopterin) Adenosine APRT Adenosine FH4 kinase Nuc. Acid AMP Glycine Thymidine (T) Adenylosucc. Alanosine PRPP + IMP glutamine HGPRT Azaserine XMP GMP Nuc. Acid Hypoxanthine Glutamine XGPRT HGPRT (H) (Eco gpt) Guanine Xanthine Mycophenolic (6-thioguanine, 6TG) (X) (8-azaguanine, 8AG) Test yourself: Fill in the boxes Grow (+) or not grow(-) Click here for the answers Growth pattern examples GHT = glycine, hypoxanthine, and thymidine A = adenine H = hypoxanthine G = glycine TG = 6-thioguanine (G analog) DAP = diaminopurine (A analog) MTX = methotrexate (DHFR inhibitor) DHFR = dihydrofolate reductase HPRT = hypoxanthine-guanine phosphoribosyltransferase APRT = adenine phosphoribosyltransferase in italics - + + -

  19. Cell mutant types: • 1. Auxotrophs (BrdU reverse selection, not discussed) • 2. Drug resistance (dominants or recessives) • 3. Temperature‑sensitive mutants: cell cycle mutants. • Tritiated amino acid suicide (aa‑tRNA synthetases) • 4. Antibodies. Lysis with complement. Targets cell surface constituents mostly (e.g., MHC) • 5. Visual inspection at colony level: • A. Sib selection (G6PD) • B. Replica plating (LDH) • C. Secreted product (Ig: anti-Ig IP) • FACS = fluorescence‑activated cell sorter (cell surface antigen or internal ligand binding protein) • Brute force (clonal biochemical analysis, e.g., electrophoretic variants (e.g., Ig, isozymes)) • MHC = major histocompatability locus or proteins • G6PD = glucose-6-phosphate dehydrogenase; • LCH = lactate dehydrogenase; Ig = immunoglobulin. IP = immunoprecipitate

  20. Cell fusion (for gene juxtaposition, mapping, protein trafficking, etc. ) Fusogenic agents PEG, Sendai virus (syncytia promoting, as HIV). Heterokaryons (2 nuclei), no cell reproduction (limited duration). (e.g., studied membrane fluidity, nuclear shuttling, gene activation (myoblasts) Hybrids (nuclei fuse, some cells (minority) survive and reproduce). Small % of heterokaryons. Complementation (e.g., auxotrophs with same requirement) allows selection Dominance vs. recessiveness can be tested. Chromosome loss from hybrids  Mapping: chromosome assignment. Synteny. Radiation hybrids: linkage analysis (sub-chromosomal regional assignments). PEG =polyethylene glycol, (available 1000 to 6000 MW)

  21. Cell fusion Hprt+, TK- + Parental cells Hprt-, TK+ HAT- HAT- PEG (polyethylene glycol, mw ~ 6000 Sendai virus, inactivated Cell fusion Heterokaryon (or, alternatively, homokaryon) HAT medium Hprt-, TK+ Hprt+ TK- Hybrid cell HAT+ Cell cycle, Nuclear fusion, Mitosis, Survival, reproducton Hprt-, TK+, Hprt+ TK- Heterokaryon use examples: membrane dynamics (lateral diffusion of membrane proteins) shuttling proteins (e.g., hnRNP A1 ), gene regulation (e.g., turn on myogenesis) Hybrid cells: examples of use: gene mapping (synteny) gene regulation (extinction) Complementation (pyrimidine path) Synteny = genes physically linked on the same chromosome are syntenic.

  22. Frye and Edidin, 1970: Use of cell fusion and heterokaryons to measure the difusio of membrane proteins Complete mixing in < 40 min. No diffusion at low temperature (<15-20 deg) http://www.erin.utoronto.ca/~w3bio315/lecture2.htm

  23. Complementation analysis Mutant parent 1 Mutant parent 2 Mutant parent 1 Mutant parent 2 gly2- + + gly3- gly1- gly1- Cell fusion Cell fusion Hybrid cell Hybrid cell glyA- glyA- glyA- glyB- Glycine-free medium: No growth No complementation same gene (named glyA) Glycine-free medium: Yes, growth Yes, complementation different genes genes (named glyA and glyB)

  24. Mapping genes to chromosomes (hybrids) Hprt- x tk-Hybrid cell (Human x Rodent) Reduced hybrid Spontaneous chromosome loss (human ~ preferentially lost) Hprt-, TK+, Hprt+ TK- Hprt-, TK+, Hprt+ TK- Just passage and wait Correlate identified chromosome loss ( ) with loss of phenotypic trait (isozyme, DNA sequence, etc.) Isozymes = enzyme variants that can be distinguished from each other by physical properties, often electrophoretic mobility in native gels (net charge).

  25. Radiation hybrids Ionizing radiation fragments the human donor cell chromosomes After fusion, some fragments are integrated into the rodent chromosomes. Checking these “reduced” hybrids for human markers (DNA restriction fragments, PCR products, or isozymes) allows conclusion about genetic linkage, the more often two markers are integrated together the closer the linkage., x Select for a human gene (e.g., hprt) to eliminate rodent parental cells (e.g., x= hprt-) Irradiated human cells die

  26. Ted Puck: mutagenesis; auxotrophic mutants in CHO cells (U. Colo.) Mary Weiss:turning off differentiation genes in cell hybrids (Institut Pasteur) Helen Blau: turning on muscle genes in heterokaryons (Stanford) Michael Edidin: 2-D diffusion of proteins in the cell membranein heterokaryons (Johns Hopkins) Frank Ruddle: mapping by chromosome segregation from cell hybrids.(Yale) nuclear-cytoplasmic shuttling in heterokaryons (Penn)

More Related